HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Timing of cisplatin administration for chemoradiotherapy in transgenic mice bearing lens tumors.

Abstract
Cisplatin-based concurrent chemoradiotherapy (CCRT) has become a standard treatment for cancer of the uterine cervix. However, there have been no investigations into the optimum timing for administration of anticancer drugs using animal models. The aim of the present study was to determine the appropriate timing for administration of the anticancer drug cisplatin in relation to delivery of radiation by assessing the antitumor activity and adverse effects of 3 different regimens in αT3 transgenic mice bearing lens epithelial tumors. CCRT showed the strongest antitumor activity. There was a significant difference between CCRT and administration of cisplatin before radiotherapy (neoadjuvant therapy) with regard to the apoptotic effect detected by TUNEL staining, but there was no significant difference between CCRT and administration of cisplatin after radiotherapy (adjuvant therapy). Assessment of adverse effects showed that there were no significant differences in the mortality rate, weight loss, anemia and leukopenia among the 3 regimens. In conclusion, these findings obtained in an animal model suggest that cisplatin should probably not be administered before irradiation, since the antitumor effect is significantly weaker than that of CCRT or administration after irradiation, while adverse effects are similar.
AuthorsShoji Kaku, Norichika Ushioda, Hiroshi Ishii, Takashi Murakami, Kentaro Takahashi, Yuichiro Nakai, Koichiro Shimoya, Takafumi Nakamura
JournalOncology reports (Oncol Rep) Vol. 32 Issue 1 Pg. 16-22 (Jul 2014) ISSN: 1791-2431 [Electronic] Greece
PMID24858487 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiation-Sensitizing Agents
  • Cisplatin
Topics
  • Animals
  • Apoptosis (drug effects, radiation effects)
  • Chemoradiotherapy (adverse effects)
  • Cisplatin (administration & dosage, adverse effects, therapeutic use)
  • Eye (drug effects, pathology, radiation effects)
  • Eye Neoplasms (pathology, therapy)
  • Female
  • Mice
  • Mice, Transgenic
  • Neoplasm Metastasis (pathology, therapy)
  • Neoplasms, Experimental
  • Radiation-Sensitizing Agents (administration & dosage, adverse effects, therapeutic use)
  • Radiotherapy (adverse effects)
  • Treatment Outcome
  • Uterine Cervical Neoplasms (pathology, therapy)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: